Pipeline

Overview

Despite significant advances in oncology, there is still a large unmet need in treating patients with solid tumors, especially those with advanced disease. Our approach begins with our proprietary computational discovery platform to identify new drug targets and biological pathways that could enhance anti-cancer immune responses. With these new targets in hand and a deep understanding of their underlying biology, we are advancing new therapeutics and optimizing their combination to expand immuno-oncology treatment options to cancer patients who are not responsive to currently available drugs.

PROGRAM TARGET PARTNER STAGE OF DEVELOPMENT Compugen-owned programs Partner programs *AZD2936 AstraZeneca TIGIT/PD-1 bispecific program* derived from COM902 Phase 1/2 Indication: Advanced or Metastatic Non-small Cell Lung Cancer Phase 1 Bayer Bapotulimab + Keytruda® ILDR2, PD-1 Indication: Head & Neck Squamous Cell Carcinoma Phase 1 Bayer Bapotulimab ILDR2 Indication: Advanced solid tumors Drug Discovery Early-Stage Programs (including Myeloid Programs) Undisclosed Phase 1 COM902 + COM701 TIGIT, PVRIG Indication: HNSCC, NSCLC, CRC (MSS) Phase 1 Indication: Advanced Solid Tumors, Multiple Myeloma COM902 TIGIT Phase 1/2 Bristol Myers Squibb COM701 + Nivolumab + BMS-986207 PVRIG, PD-1, TIGIT Indication: Ovarian, Endometrial and High PVRL-2 expressing tumors Indication: Ovarian, Breast, Endometrial and CRC (MSS) Phase 1 Bristol Myers Squibb COM701 + Nivolumab PVRIG, PD-1 Phase 1 Indication: Ovarian, Breast, Endometrial, CRC (MSS) and NSCLC COM701 PVRIG A study of a potentially first in class immunotherapy targeting PVRIG, a novel immune checkpoint computationally discovered by Compugen learn more » COM701 PVRIG A study of Compugen’s potentially first in class PVRIG antibody, COM701, in combination with Opdivo® learn more » COM701 + Nivolumab PVRIG, PD-1 A study evaluating the simultaneous triple blockade of PVRIG, PD-1 and TIGIT with Compugen’s potentially first in class anti-PVRIG antibody... learn more » COM701 + Nivolumab + BMS-986207 PVRIG, PD-1, TIGIT A study of a therapeutic antibody COM902 against the immuno-oncology target TIGIT, a novel immune checkpoint... learn more » COM902 TIGIT COM902 + COM701 - A PD-(L)1-free regimen of anti-TIGIT antibody, COM902 in combination with potentially first in class anti-PVRIG antibody, COM701 learn more » COM902 + COM701 TIGIT, PVRIG Compugen’s computation drug target discovery platform has identified multiple potential myeloid targets and is pursuing the... learn more » Early-Stage Programs Undisclosed ILDR2 is a novel immune checkpoint target with a unique mechanism of action discovered computationally... learn more » Bapotulimab ILDR2 ILDR2 is a novel immune checkpoint target with a unique mechanism of action discovered computationally... learn more » Bapotulimab + Keytruda® ILDR2, PD-1 Bispecific and multi-specific antibodies represent an emerging class of therapeutics learn more » TIGIT/PD-1 bispecific program* derived from COM902
Scroll to Top